Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1Endocrine 1

Conditions

Neoplasm Metastasis 2Colorectal Neoplasms 2Sarcoma 1Rectal Neoplasms 1Lymphoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoid Tumor 1Adenocarcinoma 1

Interventions

lanreotide 3cabozantinib 3Nivolumab 3Everolimus 3pasireotide 2lutetium Lu 177 dotatate 2ganitumab 2Sunitinib 2Octreotide 2Erlotinib Hydrochloride 2Bevacizumab 2zimberelimab 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1nintedanib 1ibrutinib 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1carfilzomib 1azaspirane 1aflibercept 1Temozolomide 1Somatostatin 1Random Allocation 1Ramucirumab 1Panitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoid Tumor × conatumumab × Clear all
NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡